OSTEOPORE LIMITED — Investor Presentation 2021

Jun 9, 2021

==> picture [694 x 169] intentionally omitted <==

INVESTOR PRESENTATION M A Y 2 0 2 1

I N V E S T O R P R E S E N T A T I O N

O S T E O P O R E . C O M

DISCLAIMER

This presentation has been prepared by Osteopore Limited and its related entities (the “Company”). It does not purport to contain all the information that a prospective investor may require in connection with any potential investment in the Company. You should not treat the contents of this presentation, or any information provided in connection with it, as financial advice, financial product advice or advice relating to legal, taxation or investment matters.

No representation or warranty (whether express or implied) is made by the Company or any of its officers, advisers, agents or employees as to the accuracy, completeness or reasonableness of the information, statements, opinions or matters (express or implied) arising out of, contained in or derived from this presentation or provided in connection with it, or any omission from this presentation, nor as to the attainability of any estimates, forecasts or projections set out in this presentation.

This presentation is provided expressly on the basis that you will carry out your own independent inquiries into the matters contained in the presentation and make your own independent decisions about the affairs, financial position or prospects of the Company. The Company reserves the right to update, amend or supplement the information at any time in its absolute discretion (without incurring any obligation to do so).

Neither the Company, nor its related bodies corporate, officers, their advisers, agents and employees accept any responsibility or liability to you or to any other person or entity arising out of this presentation including pursuant to the general law (whether for negligence, under statute or otherwise), or under the Australian Securities and Investments Commission Act 2001, Corporations Act 2001, Competition and Consumer Act 2010 or any corresponding provision of any Australian state or territory legislation (or the law of any similar legislation in any other jurisdiction), or similar provision under any applicable law. Any such responsibility or liability is, to the maximum extent permitted by law, expressly disclaimed and excluded.

Nothing in this material should be construed as either an offer to sell or a solicitation of an offer to buy or sell securiti es. It does not include all available information and should not be used in isolation as a basis to invest in the Company.

Future matters

This presentation contains reference to certain intentions, expectations, future plans, strategy and prospects of the Company. Those intentions, expectations, future plans, strategy and prospects may or may not be achieved. They are based on certain assumptions, which may not be met or on which views may differ and may be affected by known and unknown risks. The performance and operations of the Company may be influenced by a number of factors, many of which are outside the control of the Company. No representation or warranty, express or implied, is made by the Company, or any of its directors, officers, employees, advisers or agents that any intentions, expectations or plans will be achieved either totally or partially or that any particular rate of return will be achieved. Given the risks and uncertainties that may cause the Company’s actual future results, performance or achievements to be materially different from those expected, planned or intended, recipients should not place undue reliance on these intentions, expectations, future plans, strategy and prospects. The Company does not warrant or represent that the actual results, performance or achievements will be as expected, planned or intended.

US Disclosure

This document does not constitute any part of any offer to sell, or the solicitation of an offer to buy, any securities in th e United States or to, or for the account or benefit of any “US person” as defined in Regulation S under the US Securities Act of 1993 (“Securities Act”). The Company’s shares have not been, and will not be, registered under the Securities Act or the securities laws of any state or other jurisdiction of the United States, and may not be offered or sold in the United States or to any US person without being so registered or pursuant to an exemption from registration including an exemption for qualified institutional buyers.

O S T E O P O R E . C O M 2

I N V E S T O R P R E S E N T A T I O N

==> picture [1662 x 762] intentionally omitted <==

----- Start of picture text -----

TRANSFORMATIVE BONE REGENERATION PRODUCTS
PROPRIETARY 3D
BREAKTHROUGH
PRINTING TECHNOLOGY
TECHNOLOGY
Unique implants that facilitate All Osteopore products are
vascularisation to accelerate fabricated in-house using
bone and tissue regeneration low cost, proprietary 3D
printing technology
IMPROVES LIVES REVENUE INCREASING
Extremely low probability Revenue is growing as
of issues after surgery surgeons increasingly switch
compared to bone grafts from traditional products to
and permanent implants Osteopore implants
----- End of picture text -----

TARGETING THE SIGNIFICANTLY UNTAPPED US$3.9BN BONE GRAFT & US$100BN PERMANENT IMPLANT MARKET WITH SUPERIOR PRODUCTS

O S T E O P O R E . C O M 3

I N V E S T O R P R E S E N T A T I O N

Source for market size data: Allied Market Research, BCC Research

INVESTMENT HIGHLIGHTS

LOW RISK PROFILE

With significant investment already undertaken in product development and clinical trials, Osteopore is directing capital towards commercial activities

REGULATORY CLEARANCE

Osteopore’s products are cleared by

the US FDA, Australian TGA and some bear the CE mark of conformity

GROWING REVENUE

AUD$1.5 million in revenue for the twelve-

month period to 31 December 2020, with around 50,000 successful treatments to date

SCALABLE BUSINESS MODEL

High margin products with low manufacturing capital intensity provide significant opportunity to scale the business and enter new markets

HIGHLY CREDENTIALED TEAM

The Company has a highly credentialed, collaborative and experienced team to progress the commercialisation and expansion of the Company’s technology

4

I N V E S T O R P R E S E N T A T I O N

O S T E O P O R E . C O M

QUARTERLY SALES REVENUE IN SGD (THOUSAND)

$500

==> picture [1045 x 674] intentionally omitted <==

----- Start of picture text -----

$422
$391
$400
$348 $348
$328
$300
$288
$271
$219
$200
$160
$100
Q1 Q2 Q3 Q4
CY 2019 CY 2020 CY 2021
----- End of picture text -----

GROWING REVENUE & MARGINS

Record Q1 CY21 revenue of S$327,622

21% increase in over the previous year sales for the corresponding period

A gross margin of 68.2% of sales revenue was achieved in Q1 CY21

Osteopore’s cost effective and high margin manufacturing process will become a major contributor towards achieving profitability

5

I N V E S T O R P R E S E N T A T I O N

O S T E O P O R E . C O M

ROBUST CASH POSITION TO DRIVE GROWTH

Shares on Issue[A] 117.2m Total Options on Issue[B] 13.1m Market Cap @ $0.475c[C] $55.6m $47.7m EV @ $0.475[C] CASH BALANCE[D] $7.9m

FY20 Average Quarterly ($388k) Net Operating Cash Used

A: Shares on Issue includes 16.0m placement shares.

B: 9.7m options with an exercise price of $0.25 and an expiry date of 30 June 2022, 0.4m options with an exercise price of $1.00 and an expiry date in December 2022, 3m options with exercise price of $1.20 and expiry August 2023. Option incentives held by executive management, directors & advisors.

==> picture [497 x 468] intentionally omitted <==

==> picture [385 x 228] intentionally omitted <==

==> picture [386 x 218] intentionally omitted <==

==> picture [771 x 293] intentionally omitted <==

----- Start of picture text -----

ASX: OSX SHARE PRICE PAST 12 MONTHS
----- End of picture text -----

==> picture [960 x 279] intentionally omitted <==

----- Start of picture text -----

$0.80
$0.60
$0.40
$0.20
----- End of picture text -----

MAY JUNE JULY AUG SEP OCT NOV DEC JAN FEB MARCH APRIL MAY 2020 2020 2020 2020 2020 2020 2020 2020 2021 2021 2021 2021 2021

C: Market Close, 27 May 2021

D: Cash balance at 31 March 2021

O S T E O P O R E . C O M 6

I N V E S T O R P R E S E N T A T I O N

==> picture [199 x 21] intentionally omitted <==

----- Start of picture text -----

3 INNOVATE
----- End of picture text -----

==> picture [1355 x 808] intentionally omitted <==

----- Start of picture text -----

Undertaking a number of early-
stage, low-capital intensity
development projects with
large potential upside
#2 DIVERSIFY
PRODUCT RANGE
Osteopore is undertaking
Several development
#1 ACCELERATE programs to launch new
REVENUE GROWTH products and expand the
scope of bone regeneration
applications
Revenue growth from our current
product range is the highest corporate
and commercial priority and will
remain the focus throughout the
COMPANY
lifecycle of the company
VALUE
TIME FRAME
----- End of picture text -----

COMMERCIAL STRATEGY THAT BUILDS VALUE

7

I N V E S T O R P R E S E N T A T I O N

O S T E O P O R E . C O M

SCALABLE OPPORTUNITY

Osteopore has superior off-the-shelf products that can be manufactured at scale and is used in over 1.1m procedures globally

Long shelf-life products that can be stocked in a hospitals inventory system

TOTAL NUMBER OF SURGERIES IN 2020[7]

SURGERY TYPE

Craniotomy / Craniotomy closure Burr hole for hematoma evacuation Craniectomy Burr hole for shunt placement Endoscopic third ventriculostomy Cranioplasty Skull base repair Burr hole for drain placement Burr hole for biopsy Cranial reconstruction Craniosynostosis repair USG guided external ventricular drain insertion 3,845 Burr hole for exploration 3,229

359,428

302,570 89,134 74,203

65,730

51,247 48,958 46,413

33,520

19,897

11,588

1,109,764

TOTAL

8

I N V E S T O R P R E S E N T A T I O N

O S T E O P O R E . C O M

Sources located in in Appendix slide

• BREAKTHROUGH BIORESORBABLE

• PRODUCTS FOR MULTIPLE APPLICATIONS

==> picture [1167 x 848] intentionally omitted <==

----- Start of picture text -----

1.1 MILLION PROCEDURES PA
Implant that is used for
covering Burr Holes (holes
in skull) after neurosurgery
REGULATORY APPROVAL SALES GENERATING
Implant used in craniofacial
surgery to repair bone in the
skull, neck and jaw, including
repairing orbital floor fractures
REGULATORY APPROVAL SALES GENERATING
OSTEOPORE PSI
Custom-designed patient
specific implants used
throughout the body
SALES GENERATING
----- End of picture text -----

==> picture [1736 x 851] intentionally omitted <==

----- Start of picture text -----

1.1 MILLION PROCEDURES PA
Implant that is used to fill the
Implant that is used for
void following a craniotomy
covering Burr Holes (holes
(the surgical removal of part of
in skull) after neurosurgery
the bone from the skull to
expose the brain)
REGULATORY APPROVAL SALES GENERATING
REGULATORY APPROVAL SALES GENERATING
US$1BN PA []
DENTAL
DENTAL BONE GRAFT ALTERNATIVES MARKET
Dental plug which promotes
Implant used in craniofacial
vertical bone growth in the jaw
surgery to repair bone in the
following tooth removal
skull, neck and jaw, including
repairing orbital floor fractures
REGULATORY APPROVAL SALES GENERATING REGULATORY APPROVAL [†] SALES GENERATING
US$2BN PA []
ORTHOPAEDIC
OSTEOPORE PSI SALES OF ORTHOPAEDIC ALTERNATIVES
A scaffold used in a range of
Custom-designed patient
orthopaedic procedures, where
specific implants used
significant lengths of long bones
throughout the body
have been damaged
SALES GENERATING INVESTIGATIVE DEVICE SPECIAL ACCESS SALES
I N V E S T O R P R E S E N T A T I O N O S T E O P O R E . C O M 9
----- End of picture text -----

• Source for market size data: Allied Market Research, BCC Research † Regulatory approval in Singapore

==> picture [818 x 744] intentionally omitted <==

----- Start of picture text -----

Osteopore implants do not require any
major changes to current clinical procedures
----- End of picture text -----

IMPROVED PATIENT OUTCOMES & LOWER HEALTHCARE COSTS

Osteopore products address an unmet clinical need by providing readily adaptable implants and reducing complication rates after surgery

Provides hospitals, clinicians and patients with a proven solution that expediates recovery and lowers costs that may occur with traditional procedures in the event of complications

==> picture [160 x 25] intentionally omitted <==

----- Start of picture text -----

6 – 19% [1,2,3]
----- End of picture text -----

Bone Graft

REPORTED COMPLICATION RATES

==> picture [176 x 25] intentionally omitted <==

----- Start of picture text -----

25 – 33% [4,5,6]
----- End of picture text -----

==> picture [220 x 21] intentionally omitted <==

----- Start of picture text -----

Permanent Implants
----- End of picture text -----

REPORTED COMPLICATION RATES

==> picture [166 x 40] intentionally omitted <==

==> picture [84 x 22] intentionally omitted <==

----- Start of picture text -----

0.01%
----- End of picture text -----

1 0

I N V E S T O R P R E S E N T A T I O N

O S T E O P O R E . C O M

Sources listed on slide 16

REVENUE GROWTH STRATEGY

DISTRIBUTION 23 PARTNERS PARTNERS SECURED IN 13 2020

EXPANDING DISTRIBUTION NETWORK

CURRENTLY TARGETING ~1.1 million[7] CRANIAL PROCEDURES GLOBALLY

==> picture [572 x 295] intentionally omitted <==

----- Start of picture text -----

North America Europe
(293k [] ) (272k) APAC
(435k)
----- End of picture text -----*

Leverage distribution partnerships in the key markets to accelerate revenue growth

Ensure sales teams and surgeons are educated and supported to drive adoption and sales

Leverage early adopters in sales and marketing campaigns to achieve product sales momentum

Increase underlying revenue through a mix of geographic expansion and adjacent clinical applications

O S T E O P O R E . C O M 1 1

I N V E S T O R P R E S E N T A T I O N

• In brackets, the number of cranial procedures undertaken in 2020.

FOUNDATIONAL MARKETS

==> picture [466 x 278] intentionally omitted <==

ASIA

Well established and experienced distribution partner network in South Korea, Vietnam, Singapore and Australia 2020 constant currency year-on-year revenue growth of 39%

Expanded range of clinical applications, including aesthetic surgery

Emerging dental application sales in Singapore

Orthopaedic application clinical trials underway in Singapore, Vietnam and Malaysia

==> picture [297 x 257] intentionally omitted <==

AUSTRALIA & NZ

Hired dedicated Business Development person in Sydney Australia

Signed Australian & NZ distribution agreement with LMT Surgical Education and training for LMT sales team

Achieve initial sales

Support clinical trial for dental application

O S T E O P O R E . C O M 1 2

I N V E S T O R P R E S E N T A T I O N

==> picture [123 x 184] intentionally omitted <==

==> picture [896 x 458] intentionally omitted <==

----- Start of picture text -----

PRIORITY MARKET EXPANSION
CHINA
USA
----- End of picture text -----

Recently received CE Mark for expanded product variants and shelf life Europe + UK Signed German-Austrian Distribution Agreement with MTG Medizintechnik Göhl GmbH Initial stocking order for Osteopore products from MTG Medizintechnik Göhl GmbH Identify & engage with Key Opinion Leaders surgeons across broader Europe + UK Achieve initial stocking orders

USA Signed US Distribution Agreement with Bioplate First “stocking” order with Bioplate Education and training for Bioplate sales team Secure additional U.S. distribution partnerships to cover more states Initiate 510k regulatory approval for dental and orthopedic products

Signed Co-operation agreement with Boao Yiling Life Care Centre in China Establish a subsidiary in the Suzhou Industrial Park as the first step towards obtaining Chinese regulatory approval Prepare NMPA dossier for regulatory approval

==> picture [75 x 66] intentionally omitted <==

==> picture [140 x 116] intentionally omitted <==

==> picture [113 x 84] intentionally omitted <==

==> picture [77 x 19] intentionally omitted <==

----- Start of picture text -----

JAPAN
----- End of picture text -----

Identify and engage KOL surgeons interested in adopting Osteopore products Identify potential distribution partners with strong ties to hospitals specialising in craniofacial procedures Develop the necessary education and training materials

Achieve initial stocking order

O S T E O P O R E . C O M 1 3

I N V E S T O R P R E S E N T A T I O N

REGENERATION OF OTHER TISSUE

Osteopore has successfully completed animal trials for knee cartilage regeneration, and the Osteopore scaffold may also potentially be used to assist with the regeneration of other tissue types

==> picture [439 x 81] intentionally omitted <==

----- Start of picture text -----

ACCELERATING BONE REGENERATION
----- End of picture text -----

Osteopore is investigating the viability of incorporating compounds to produce novel polycaprolactone polymer composites which could be used development additional products for adjacent therapeutic and surgical areas

==> picture [438 x 82] intentionally omitted <==

----- Start of picture text -----

VETERINARY MARKETS
----- End of picture text -----

Osteopore has successfully completed multiple animal trials for a number of different surgical applications which could possibly translate into products for the veterinarian market

FUTURE COMMERCIAL OPPORTUNITIES

Osteopore is conducting several earlystage research initiatives with high quality institutions that could present significant commercial opportunities.

O S T E O P O R E . C O M 1 4

I N V E S T O R P R E S E N T A T I O N

2021 COMMERCIAL PRIORITIES

==> picture [675 x 854] intentionally omitted <==

----- Start of picture text -----

DIVERSIFICATION
Leverage dental product regulatory
approval in Singapore to drive sales in Asia
Initiate a dental clinical trial in Australia as
the basis for TGA product approval
Initiate FDA approval for dental and
orthopaedic products for sale in the USA
Initiate regulatory approval
for rhinoplasty in Korea
----- End of picture text -----

==> picture [689 x 804] intentionally omitted <==

----- Start of picture text -----

ACCELERATE REVENUE GROWTH
Leverage cranial and maxillofacial products with
regulatory approval in significant Markets:
Asia USA Germany
Australia & NZ Scandinavia
Establish a presence in new markets with
a high volume of relevant procedures:
China UK Japan
----- End of picture text -----

==> picture [489 x 371] intentionally omitted <==

----- Start of picture text -----

INNOVATION
----- End of picture text -----

==> picture [400 x 90] intentionally omitted <==

----- Start of picture text -----

Experiment with promising novel compound
combinations, including PCL-TCP and PCL-TCP-
Mg, facilitating bone and cell growth to
improve healing time and patient outcomes
----- End of picture text -----

Engage with Terumo BCT to explore the opportunities to combine Osteopore’s resorbable biomimetic scaffolds with Terumo’s autologous biologics

Continuously improve manufacturing efficiency using proven technological improvements in 3D printing to cost effectively scale production

O S T E O P O R E . C O M 1 5

I N V E S T O R P R E S E N T A T I O N

SOURCES

• 1 Dimitriou, R., Mataliotakis, G. I., Angoules, A. G., Kanakaris, N. K., & Giannoudis, P. V. (2011). Complications following autologous bone graft harvesting from the iliac crest and using the RIA: a systematic review. Injury , 42, S3-S15.

• 2 Younger, E. M., & Chapman, M. W. (1989). Morbidity at bone graft donor sites. Journal of orthopaedic trauma , 3(3), 192-195.

• 3 Arrington, E. D., Smith, W. J., Chambers, H. G., Bucknell, A. L., & Davino, N. A. (1996). Complications of iliac crest bone graft harvesting. Clinical Orthopaedics and Related Research ®, 329, 300-309

• 4 Giese, H., Meyer, J., Unterberg, A., & Beynon, C. (2020). Long-term complications and implant survival rates after cranioplastic surgery: a single-center study of 392 patients. Neurosurgical Review , 1-9.

• 5 Wiggins, A., Austerberry, R., Morrison, D., Ho, K. M., & Honeybul, S. (2013). Cranioplasty with custom-made titanium plates—14 years experience. Neurosurgery , 72(2), 248-256.

• 6 Thien, A., King, N. K., Ang, B. T., Wang, E., & Ng, I. (2015). Comparison of polyetheretherketone and titanium cranioplasty after decompressive craniectomy. World neurosurgery , 83(2), 176-180.

• 7 cetas healthcare (2020). Market research conducted for Osteopore on the global cranial procedure market.

• 8 Sparks, D. S., Saifzadeh, S., Savi, F. M., Dlaska, C. E., Berner, A., Henkel, J., ... & Hutmacher, D. W. (2020). A preclinical large-animal model for the assessment of critical-size load-bearing bone defect reconstruction. Nature protocols , 15(3), 877-924.

• 9 Zhang, Z., & Teoh, S. H. (2014). Novel 3D polycaprolactone scaffold for ridge preservation – a pilot randomised controlled clinical trial. Clinical Oral Implants Research , 26, 271-277.

• 10 van Griensven, M., Biberthaler, P., & Rosado Balmayor, E. (2015). Clinical approaches to the healing of long bone defects. In Schantz, J-T. & Hutmacher, D.W. (2020), Advanced Therapies in Regenerative Medicine , Vol. 2, World Scientific, (pp. 217-231).

O S T E O P O R E . C O M 1 6

I N V E S T O R P R E S E N T A T I O N

==> picture [694 x 169] intentionally omitted <==

Carl Runde Chief Financial Officer M +61 400 118 017 E: carl_runde@osteopore.com

1 7

I N V E S T O R P R E S E N T A T I O N

O S T E O P O R E . C O M